Group by Gene: Include preclinical: Chemotherapy DNA CD Protein Inhibitors Immune Checkpoint Inhibitors Immunotherapy Tyrosine Kinase Inhibitors FGF BCL Inhibitors | PD1 inhibitor pembrolizumab | nivolumab | envafolimab | PD-L1 inhibitor atezolizumab | PD-L1 inhibitor | HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor fam-trastuzumab deruxtecan-nxki | CLDN18.2 inhibitor zolbetuximab | Thymidylate synthase inhibitor 5-fluorouracil | HER2 inhibitor trastuzumab | HER2 inhibitor | Multi-tyrosine kinase inhibitor pazopanib | nintedanib | PD-L1 inhibitor, HER2 inhibitor trastuzumab + avelumab | ALK inhibitor crizotinib | c-MET inhibitor RG3638 | AMG 102 | VEGFR inhibitor, FGFR1 inhibitor, PD1 inhibitor toripalimab-tpzi + surufatinib | Microtubule stabilizer, Tubulin polymerization promoter, DNA synthesis inhibitor, Thymidylate synthase inhibitor cisplatin + docetaxel + 5-fluorouracil | HER2 inhibitor, PD1 inhibitor pembrolizumab + trastuzumab | pembrolizumab + margetuximab | Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor, Thymidylate synthase inhibitor cisplatin + paclitaxel + capecitabine | FGFR inhibitor futibatinib | Immunotherapy Immunotherapy |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No biomarker | |||||||||||||||||||||||
HER-2 overexpression | |||||||||||||||||||||||
HER-2 underexpression | |||||||||||||||||||||||
HER-2 amplification | |||||||||||||||||||||||
HER-2 negative | |||||||||||||||||||||||
HER-2 positive | |||||||||||||||||||||||
HER-2 1899‐1G>A | |||||||||||||||||||||||
PD-L1 expression | |||||||||||||||||||||||
PD-L1 underexpression | |||||||||||||||||||||||
MET amplification | |||||||||||||||||||||||
CLDN18.2 positive | |||||||||||||||||||||||
CLDN18.2 expression | |||||||||||||||||||||||
MET expression | |||||||||||||||||||||||
ATR mutation | |||||||||||||||||||||||
ATRX mutation | |||||||||||||||||||||||
ATM mutation | |||||||||||||||||||||||
MSI-H/dMMR | |||||||||||||||||||||||
HER-2 negative + PD-L1 expression | |||||||||||||||||||||||
CPEB1 underexpression | |||||||||||||||||||||||
FGFR3 amplification | |||||||||||||||||||||||
CDKN2A deletion | |||||||||||||||||||||||
MDM4 amplification | |||||||||||||||||||||||
MDM2 amplification | |||||||||||||||||||||||
Chr amplification(11)(q13) | |||||||||||||||||||||||
CMTM6 expression + PD-L1 expression | |||||||||||||||||||||||
CDKN2B deletion | |||||||||||||||||||||||
FGFR2 amplification | |||||||||||||||||||||||
CMTM4 expression + PD-L1 expression |